The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by beta-adrenergic blockade
- PMID: 7859237
The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by beta-adrenergic blockade
Abstract
Milrinone is an inotropic and vasodilator agent proven to be effective in the treatment of heart failure. This study evaluated whether milrinone produces inotropic and hemodynamic effects independent of reflex adrenergic stimulation. Eleven stable heart failure patients (New York Heart Association class II to III) undergoing cardiac catheterization received intravenous (i.v.) milrinone (50 micrograms/kg for 10 minutes followed by 0.5 micrograms/kg/min for 50 minutes) during beta-adrenergic blockade. After beta-blockade with a 50-mg oral dose of metoprolol, heart rate decreased by a mean of 16.6%. The peak inotropic response to i.v. milrinone measured using the maximum rate of rise of left ventricular pressure (LV dP/dt) was fully developed at 20 minutes. Mean absolute inotropic response of LV dP/dt from baseline was statistically significant at 10, 20, 30, and 40 minutes (P < 0.05). Mean percentage increase in cardiac index from baseline was statistically significant at 20 and 30 minutes, and mean absolute decline from baseline for pulmonary capillary wedge pressure was statistically significant at 20 and 40 minutes (P < 0.05). The inotropic and hemodynamic effects of i.v. milrinone were thus preserved during beta-adrenergic blockade. This finding is consistent with a mechanism of action of i.v. milrinone--myocardial phosphodiesterase inhibition--that is independent of reflex adrenergic stimulation.
Similar articles
-
Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.Circulation. 1986 Mar;73(3 Pt 2):III175-83. Circulation. 1986. PMID: 3510774 Clinical Trial.
-
A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure.Can J Cardiol. 1991 Jan-Feb;7(1):5-10. Can J Cardiol. 1991. PMID: 2025794 Clinical Trial.
-
Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension.J Am Coll Cardiol. 1996 Dec;28(7):1775-80. doi: 10.1016/S0735-1097(96)00399-3. J Am Coll Cardiol. 1996. PMID: 8962566
-
Milrinone, a new agent for the treatment of congestive heart failure.Clin Pharm. 1986 Mar;5(3):201-5. Clin Pharm. 1986. PMID: 3514085 Review.
-
In vivo studies of myocardial beta-adrenergic receptor pharmacology in patients with congestive heart failure.Circulation. 1990 Aug;82(2 Suppl):I44-51. Circulation. 1990. PMID: 2164896 Review.
Cited by
-
Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.Curr Cardiol Rep. 2001 May;3(3):224-31. doi: 10.1007/s11886-001-0027-8. Curr Cardiol Rep. 2001. PMID: 11305977 Review.
-
Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure.World J Cardiol. 2016 Jul 26;8(7):401-12. doi: 10.4330/wjc.v8.i7.401. World J Cardiol. 2016. PMID: 27468333 Free PMC article. Review.
-
Rational use of inotropic therapy in heart failure.Curr Cardiol Rep. 2001 Mar;3(2):108-13. doi: 10.1007/s11886-001-0035-8. Curr Cardiol Rep. 2001. PMID: 11177666 Review.